- 1 Title: Management of Antipsychotics in Primary Care: Insights from Healthcare
- 2 Professionals and Policy Makers in the UK
- 3 Short Title: Antipsychotic Management in Primary Care
- 4 Alan A. Woodall<sup>1,2</sup>, Aseel S. Abuzour<sup>3</sup>, Samantha A. Wilson<sup>4</sup>, Frances S. Mair<sup>5</sup>, Iain Buchan<sup>6</sup>,
- 5 Sally B. Sheard<sup>4</sup>, Paul Atkinson<sup>4</sup>, Dan W. Joyce<sup>6</sup>, Pyers Symon<sup>\*</sup>, Lauren E. Walker<sup>7</sup>
- 6
- 7 AW ORCID: <u>0000-0003-2933-0508</u>
- 8 AA ORCID: <u>0000-0002-4073-4346</u>
- 9 SW ORCID: <u>0000-0002-7959-052X</u>
- 10 FM ORCID: <u>0000-0001-9780-1135</u>
- 11 IB ORCID: <u>0000-0003-3392-1650</u>
- 12 SS ORCID: <u>0000-0001-8116-9120</u>
- 13 PA ORCID: <u>0000-0001-8740-6561</u>
- 14 DJ ORCID: <u>0000-0002-9433-5340</u>
- 15 LW ORCID: 0000-0002-3827-4387
- 16

#### 17 Author Affiliations:

- <sup>1</sup>Department of General Practice and Mental Health, Institute of Population Health,
- 19 University of Liverpool, UK
- 20 <sup>2</sup>Powys Teaching Health Board, Bronllys Hospital, UK
- 21 <sup>3</sup>Unit for Ageing and Stroke Research, School of Medicine, University of Leeds, UK NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

<sup>4</sup>Department of Public Health, Policy and Systems, Institute of Population Health, University

23 of Liverpool, UK

<sup>5</sup>General Practice & Primary Care, School of Health and Wellbeing, University of Glasgow, UK

- <sup>6</sup>NIHR Mental Health Research for Innovation Centre, University of Liverpool, UK
- <sup>7</sup>Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and
- 27 Integrative Biology, University of Liverpool, UK
- \*PS is public advisor (no ORCID ID; address withheld; contact via corresponding author)

29

#### 30 ABSTRACT

31 Introduction: Antipsychotic medication is increasingly prescribed to patients with serious

32 mental illness. Patients with serious mental illness often have cardiovascular and metabolic

33 comorbidities, and antipsychotics independently increase the risk of cardiometabolic

34 disease. Despite this, many patients prescribed antipsychotics are discharged to primary

35 care without planned psychiatric review. We explore perceptions of healthcare

36 professionals and managers/planners of policy regarding management of antipsychotics in

37 primary care.

Methods: Qualitative study using semi-structured interviews with 11 general practitioners
(GPs), 8 psychiatrists, and 11 managers/planners of policy in the United Kingdom. Interviews
were studied using inductive thematic analysis.

**Results:** Respondents reported competency gaps that impaired ability to manage patients
prescribed antipsychotic medications holistically, arising from inadequate postgraduate
training and professional development. GPs lacked confidence to manage antipsychotic
medications alone; psychiatrists lacked skills to address cardiometabolic risks and did not

45	perceive this as their role. Communication barriers, lack of integrated care records, limited
46	psychology provision, lowered expectation of patients with serious mental illness by
47	professionals, and pressure to discharge from hospital resulted in patients in primary care
48	becoming 'trapped' on antipsychotics, inhibiting opportunities to deprescribe.
49	Organisational and contractual barriers between organisations exacerbate this risk, with
50	socioeconomic deprivation and lack of access to non-pharmacological alternatives driving
51	overprescribing. GPs and psychiatrists voiced professional fears of being blamed if an event
52	causing harm occurred after stopping an antipsychotic, which inhibited deprescribing. A
53	range of actions to overcome these barriers were suggested.
54	<b>Conclusions:</b> People prescribed antipsychotics experience a fragmented health system and
55	suboptimal care. Many simple steps could be taken to improve quality of care for this
56	population but inadequate availability of non-pharmacological alternatives and
57	socioeconomic factors increasing mental distress need key policy changes to improve the
58	current situation.
59	
60	INTRODUCTION
61	Psychiatrists usually prescribe antipsychotic medication (APM) to treat serious mental illness

62 (SMI) such as schizophrenia and bipolar affective disorder. Despite treatment, patients with

63 SMI die 10-20 years prematurely, mainly from cardiometabolic diseases and cancer [1-5]. In

- 64 recent years, 'atypical' APMs are increasingly prescribed due to reports of fewer
- 65 extrapyramidal effects [6], but they confer increased risk of obesity, type-2 diabetes
- 66 mellitus, and cardiovascular disease [5, 7], and require ongoing clinical monitoring of
- 67 cardiometabolic risk factors to ameliorate these risks, including body mass index, blood

3 of 39

pressure, lipid and glucose levels and monitoring for QTc prolongation on electrocardiogram 68 (ECG) [8-10]. While APM are licensed for SMI, increased prescribing for personality disorder 69 [11], depression [12], anxiety [13] insomnia [14], dementia [15], learning disability [16] and 70 autistic spectrum disorder [17] is occurring. Currently, in the UK, only quetiapine is licensed 71 72 as a treatment for depression, and risperidone is licenced for short-term use to manage aggression in patients with moderate to severe Alzheimer's dementia; all other uses are off-73 licence [18]. In some countries, such as Norway, APM are regularly initiated by GPs [19]. In 74 75 the UK however, APM initiation is mainly undertaken by psychiatrists; traditionally, where the patient remains under secondary care (outpatient clinic or hospital care led by a 76 psychiatrist), psychiatrists optimise APM, and GPs mainly monitor cardiometabolic risk [20, 77 78 21]. Unfortunately, many patients with SMI who attend psychiatric appointments are less 79 likely to attend their GP for physical health follow-up [20, 21]. Many international health 80 systems, mainly designed to manage acute rather than chronic illness, struggle to provide 81 continuity of care to patients with chronic mental illness [22]. Patients taking APM deemed 82 stable from a psychiatric perspective, or who do not have psychotic illnesses, are often discharged by psychiatrists to be managed solely by GPs, which blurs this traditional division 83 of care and potentially leaves gaps in integrated care for these patients [23]. APM 84 85 prescribing is increasing [6]; approximately 32% of patients with SMI who are often prescribed APM long-term do not have specialist psychiatric reviews [24]. This study 86 87 explores the management of patients taking APM discharged to primary care. We explored the views of healthcare professionals (HCPs) who deliver this care and managers/planners 88 or directors of policy (MDPs) of the health organisations where APM prescribing is occurring 89 90 in the UK. The aim of this study was to identify potential barriers and facilitators of holistic 91 care for people taking APM and views on the causes of increasing APM prescribing.

4 of 39

92

#### 93 METHODS

#### 94 Design and Setting

- 95 Qualitative study to explore views of professionals and policymakers involved in care of
- 96 patients prescribed APM in primary care, by conducting semi-structured interviews with
- 97 participants recruited from the UK. The 'Consolidated criteria for reporting Qualitative
- 98 Research' guided study design and analysis of results [25].

99

#### 100 Participants and Recruitment

101 Participants were recruited from England, Scotland, and Wales between 1<sup>st</sup> July 2022 and

102 March 31<sup>st</sup> 2023, and included GPs and psychiatrists; some held additional roles as service

103 managers or policy directors. In addition to HCPs, NHS managers, government advisors and

104 policy directors from stakeholders (e.g., mental health charities, Royal Colleges) were also

105 invited. Purposive sampling identified potential participants, who were sent study

- 106 information and an invite to participate. Up to three invites were sent; if no response was
- 107 received, attempts to recruit ceased. Participants were briefed about the study with

108 researchers and written consent obtained prior to interview. Participants could withdraw

109 consent at any time, including after interview.

110

111

112

#### 113 Data Collection

114	Semi-structured interviews were undertaken between July 2022 and May 2023, and basic
115	details of participant characteristics (professional role, whether clinicians had postgraduate
116	experience of psychiatry and general practice, and duration of UK professional registration)
117	were obtained. Interview schedules were developed and refined by the team (see
118	supplemental file 1). Interviews were conducted by AW (clinician in general practice and
119	psychiatry with qualitative research experience) and explored views on management of
120	APM prescribing, barriers to holistic care and causes of increasing APM prevalence in the
121	population. Interviews were conducted via Microsoft Teams. Audio data was transcribed
122	verbatim and anonymised; each participant was assigned a code, then recordings deleted.
123	Transcripts were not provided to participants for checking; no withdrawal of consent
124	occurred after interview. Data collection and analysis were undertaken concurrently.

125

#### 126 Data Analysis

127 Interview transcripts were analysed using inductive thematic analysis, using Braun and 128 Clarke's methodology [26] to determine themes by constant comparison and ensuring data saturation was reached. QSR NVivo® Windows (Version 1.6) was used to organise, code, and 129 analyse transcripts. Transcripts were repeatedly re-read to familiarise researchers with the 130 data. This was followed by generation of initial codes, identifying themes and subthemes, 131 132 and refining these to ensure final theme definitions reflected meaning within the data. The 133 iterative categorisation of data into themes and subthemes, and interpretation of the data were undertaken by the coding team (AW, AA, SW, LW) to ensure analytical rigour and 134 135 plausibility.

#### 136

#### 137 Patient and Public Involvement

- 138 A public advisor (PS) provided input to protocol design, study progress, analysis, and
- interpretation of results.

140

### 141 Ethics statement

- 142 The study received ethical approval from the Health Research Authority (IRAS: 311503) via
- 143 NHS Research Ethics Committee-06 (22/WA/0173).

144

#### 145 **RESULTS**

- 146 Table 1 shows characteristics of participants; due to the national role of some MDPs, certain
- 147 identifiable characteristics have been withheld to protect their anonymity. Of 46 subjects
- approached (20 GPs, 13 psychiatrists, 13 MDPs), 30 subjects (11 GPs, 8 psychiatrists, and 11
- 149 MDPs) consented to interviews, lasting between 21-58 minutes (mean 41 minutes).

150

### 151 Table 1: Characteristics of participants

152

Participant ID	Role	Sex	Postgraduate UK training experience in psychiatry and general practice?	Time on relevant UK professional register
GP-01	GP partner	Male	Yes	21 years
GP-02	Salaried GP	Male	Yes	22 years
GP-03	GP partner	Female	Yes	16 years
GP-04	Salaried GP	Male	Yes	16 years
GP-05	GP partner	Male	Yes	21 years
GP-06	GP partner	Male	No	32 years

GP-07	Salaried GP	Male	Yes	8 years
GP-08	GP partner	Female	Yes	21 years
GP-09	GP partner	Male	No	11 years
GP-10	GP partner	Female	Yes	20 years
GP-11	GP partner	Female	Yes	21 years
PSY-01	Consultant	Male	No	19 years
	Psychiatrist			,
PSY-02	Consultant	Male	No	25 years
	Psychiatrist			
PSY-03	Associate Specialist in	Male	No	30 years
	Psychiatry			
PSY-04	Consultant Nurse in	Male	No	27 years
	Psychiatry			
	(Responsible			
	Clinician)			
PSY-05	Consultant	Male	No	21 years
	Psychiatrist			
PSY-06	Consultant	Female	No	17 years
	Psychiatrist			
PSY-07	Specialty doctor in	Male	No	10 years
	Psychiatry			
PSY-08	Consultant	Male	No	22 years
	Psychiatrist			
MDP-01	Former Educational	Withheld	No (also a consultant	Withheld
	advisor (psychiatry) to		psychiatrist)	
	national postgraduate			
	training			
	committee and Royal			
	College of Psychiatrists			
MDP-02	Policy Director, mental	Withheld	N/A	N/A
	health charity			
MDP-03	Government advisor	Withheld	Withheld	Withheld
	on mental health			
MDP-04	Former executive	Withheld	Yes (also a GP)	Withheld
	officer of Royal College			
	of General			
	Practitioners	<b>N A</b> = <b>I</b> =		
INIDP-05	Nedical Director of	iviale	res (also a GP)	withheid
	rogion			
	Director of Mantal	Mithhald		Mithhald
		withineid	withneid	withineid
	nealth Services for			
	provider organisation			

medRxiv preprint doi: https://doi.org/10.1101/2023.11.13.23298487; this version posted November 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

MDP-07	Director of Primary Care for a provider organisation	Withheld	Withheld	Withheld
MDP-08	Chief Pharmacist for a provider organisation	Withheld	Withheld	Withheld
MDP-09	Medical Director for a provider organisation	Male	Yes (also a GP)	Withheld
MDP-10	Representative of General Practitioners Committee (British Medical Association)	Withheld	Yes (also a GP)	Withheld
MDP-11	Former executive officer of General Practitioner Committee of British Medical Association	Withheld	Yes (also a GP)	Withheld

153

154

Five themes emerged that affected APM management in primary care: (1) Confidence of 155

156 HCPs around holistic management of APM; (2) Service pressures 'trapping' patients on APM

in primary care; (3) Communication barriers between primary and secondary care; (4) 157

Lowered expectations of patients by HCPs; (5) Strategic factors, such as contractual 158

159 divisions between primary and secondary care, worsening socioeconomic inequality causing

160 mental distress, and medicolegal fears of HCPs, affected whether patients remain on APM.

Themes (with illustrative quotes) are discussed below, and additional supporting quotes are 161

162 available (see supplemental file 2). At the end of each theme, potential facilitators of

optimal care suggested by respondents are discussed, with suggested actions for clinicians 163

and MDPs at both local and national levels. 164

165

#### 166 1. Confidence of HCPs around holistic management of APM

167 Holistic care of patients taking APMs requires HCPs trained to manage both mental and

physical health concerns. Both GPs and psychiatrists lacked confidence to address both 168

169	mental and physical health concerns holistically, with many patients facing fragmented care
170	as a result, where focus was either primarily on mental health, or physical health, but rarely
171	both. HCPs described inadequate postgraduate training and limited opportunity to retain
172	skills after specialist qualification as contributing factors to their perceived competency
173	gaps. Three subthemes emerged:
174	
175	(a) GPs were reluctant to manage APM without psychiatrist support
176	Most GPs felt their training did not encompass APM management and therefore felt
177	inadequately skilled to manage APM prescribing without psychiatrist support. At the same
178	time, GPs were concerned that patients might lack confidence in their ability to advise on
179	APMs appropriately:
180	"I don't think that my [junior doctor psychiatric] training necessarily made me more
181	confident in relation to antipsychotics I don't think I'm confident enough to do that
182	without some input." (GP-07)
183	<i>"It's not just a GP thingthe patient might not have the confidence in us to do it</i>
184	either They've often demanded to be referred to psychiatry, because the GP
185	couldn't make them better to be then told by the same GP 'well actually I'm going
186	to stop your antipsychotic'- the patient may not have the confidence that stopping it
187	will be OK." (GP-11)
188	Psychiatrists recognised GPs' reluctance to manage APM when patients were discharged to

189 primary care, but some psychiatrists felt GPs should be able to manage APM:

190	"Your average GP has excellent capabilities to manage someone on antipsychotics
191	The thing I think they lack would be the confidence to do so." (PSY-01)
192	Potential facilitators to help GPs manage more patients prescribed APM independently
193	included direct support from pharmacists, who would have additional training in psychiatric
194	medication, to support appropriate APM optimisation while remaining in primary care:
195	"Psychiatry pharmacists are very easy to contact they tend to give detailed letters
196	as towhat you could do. There are alternatives. I wouldn't necessarily make a
197	decision straight away without just sending the pharmacists a quick letter to say,
198	"this is a situation what would your advice be" and they might say
199	"aripiprazoleand then you need to do x y z". And that would probably give me
200	more confidence. I don't think I would just switch than myself because I don't
201	necessarily have the confidence or the knowledge to do that." (GP-07)
202	

#### 203 (b) Psychiatrists were reluctant to address cardiometabolic risks

Respondents felt psychiatrists often disregarded cardiometabolic risks. Psychiatrists explained that they felt they lacked the necessary skills to enable them to adequately address cardiometabolic risks, but there was also a reluctance in some to consider this might be part of their role. Many respondents felt this meant a missed opportunity to intervene in cardiometabolic risk for some patients, as they acknowledged many patients with SMI might not attend for GP follow up as expected, and this puts them at greater risk of suboptimal management and poorer long-term outcomes:

211 *"I received no training in general practice... that's never been part of my psychiatric* 

212 training. The idea that I would comfortably manage hypertension or diabetes... I

- 213 *don't feel comfortable with it at all."* (PSY-07)
- 214 *"It's all 'go and talk to your GP'... that's another step in the loop... and the patient*
- 215 often doesn't go." (MDP-10)

216 GPs understood psychiatrists' reluctance to initiate medications for cardiometabolic risks

217 but criticised a lack of non-pharmacological interventions (e.g., referrals to dieticians or

smoking cessation services), with the expectation that GPs would undertake all of these.

219 Some also noted that psychiatrists rarely made changes to APM to ameliorate

220 cardiometabolic risks, their focus being solely on addressing psychiatric issues:

221 *"There is...mention in some letters about us helping the patient control lifestyle* 

222 factors... What I don't [see] is any evidence in letters that those referrals have been

223 made by the psychiatric teams themselves." (GP-11)

224 "Your focus tends to be on mental health...when you're seeing someone in their 20s

225 [with] acute psychotic illness and their life is coming apart - you're focusing on that,

and you are thinking 'they might die of heart disease when they're 60? If I get them

227 to 60, I've done really well!" "(PSY-01).

228 Respondents felt having contracted GP support embedded in mental health teams,

229 particularly for inpatient units to manage physical health risks, would overcome some of

- 230 psychiatrists' lack of confidence around physical health interventions, and ensure that
- 231 patients had holistic care prior to discharge. Others thought non-medically qualified

232	assistants, such as health care support workers to co-ordinate and ensure physical health
233	monitoring occurred, would be of help in community mental health teams:

- 234 *"Either we make primary care accessible to that group of people or we embed*
- 235 generalists within mental health services. And I think it's going to be probably easier
- to embed people with good general physical health monitoring and physical health
- 237 intervention skills within mental health, because we know that our group of patients
- tend to be the most resistant and wouldn't necessarily present to a GP". (MDP-06)
- 239

#### 240 (c) Gaps for HCPs in postgraduate and post-speciality training

241	HCPs reported inadequate training to manage both psychiatric and cardiometabolic aspects
242	of APMs. While 14/16 (88%) GPs interviewed had undertaken postgraduate psychiatric
243	training, no psychiatrist interviewed had any postgraduate training in general practice (Table
244	1). This impaired mutual understanding of each other's specialty: some psychiatrists thought
245	it was a requirement that all GPs undertook psychiatric postgraduate training, and this
246	partially drove the expectation that, therefore, GPs could manage APMs. It was of note that
247	no psychiatrist stated they would have benefitted from postgraduate experience in primary
248	care. Respondents confirmed postgraduate GP training did not cover APM management:
249	"I think [GP trainees] were treated differently [to psychiatric trainees]. It was felt
250	that they didn't need that sort of in-depth knowledge [around APM management]."
251	(PSY-05)
252	"I would have initially thought that GPs would have all had to have done some

253 training in [psychiatry], so am I'm wrong in that? [interviewer explains some GPs

13 of 39

have no psychiatric placement] ... I'm actually shocked.... I had the impression that
they had to do a stint in psychiatry." (PSY-04)

GPs were worried that other stakeholders wanted them to manage more patients on APM
without appreciating the unsustainable volume of specialist secondary care work being
transferred to GPs:

259 "The special interest groups are saying, 'Well, actually, this is not complicated... if 260 you do some online teaching for an hour then the GP should know enough'.... It's not 261 possible, because we can't keep up to date with all the different antipsychotics... as 262 well as keeping up to date with all the different specialities and their specialist

263 *medications."* (GP-11)

264 Psychiatrists confirmed they had little postgraduate specialty training on cardiometabolic

risks of APM and MDPs involved in training confirmed this gap in the psychiatric curriculum.

266 One MDP (a former director of postgraduate psychiatric training) felt that psychiatric

trainees should have some exposure to working in general medicine or primary care to

268 improve their holistic skills and gain a better understanding of how primary care functions:

269 *"It doesn't seem to be built into the curriculum. I don't directly influence what's going* 

270 on in the [Royal College of Psychiatrists] anymore... I don't know what it says in terms

271 of speaking to physical health.... for] adult psychiatry trainees.... [we need] to give

272 them more experience of working in.... primary care, or could be on an acute medical

273 assessment unit... I think [it] would help." (MDP-01)

274 There was a concern by GPs and psychiatrists that psychiatric vocational training placements

275 for GPs were often unsuitable to gain relevant psychiatric experience (e.g., GP trainees

276	placed in forensic hospital posts with a low turnover of acutely unwell patients) and felt
277	there was little recognition by both relevant Royal Colleges (who oversee postgraduate
278	curricula for medical graduates in the UK) that management of APM was increasingly falling
279	to GPs, as more patients were discharged to primary care. Many felt that this needed to be
280	addressed by improved curriculum design and better co-ordination between the Royal
281	College of General Practitioners (RCGP) and Royal College of Psychiatrists (RCPsych). Others
282	felt there needed to be attitudinal changes within the psychiatric profession, which had to
283	be led by the RCPsych, to accept that physical health concerns, often arising from APM side
284	effects, was their responsibility to deal with:
285	If it's a sequelae from their medications, I think they should be training on looking at
286	ECGs and looking for QTc abnormalities, management of diabetes and QRISK
287	[cardiovascular risk assessment] - I think would be sensible. (MDP05)
288	GPs felt continuous professional development (CPD) sessions with psychiatrists were
289	needed, to look at holistic care of patients on APMs (with both specialities on an equal
290	footing, rather than psychiatrists 'lecturing GPs on what they need to do'), reflecting the
291	need for both specialities to develop strategies and shared protocols to improve integrated
292	care:
293	"I would love to see our [CPD] sessions return to in-person, face-to-face, group-based
294	multidisciplinary sessions And I would like that to be all inclusive across our health
295	board. It's a brilliant opportunity that we've got to develop beyond primary care."
296	[MDP-09]

297

#### 298 2. Service pressures 'trapping' patients on antipsychotics in primary care

299	Respondents felt service pressures had increased APM prescribing, with three main
300	subthemes emerging. Many voiced concerns about difficulty obtaining psychological
301	interventions for patients, which meant both GPs and psychiatrists often had no recourse
302	but to prescribe APM to help patients cope, especially for patients with non-psychotic
303	illnesses including personality disorder, anxiety, and insomnia. Psychiatrists explained they
304	were often under pressure to quickly discharge patients back to primary care, and this also
305	contributed to prescribing APM to enable this to happen. However, GPs were concerned
306	that when cardiometabolic risks were accruing in patients secondary to APM, many
307	psychiatrists were reluctant to accept referrals back to their service for medication reviews:
308	
309	(a) Limited psychology provision
310	Respondents, particularly psychiatrists, felt limited psychology provision forced APM
311	prescribing, often used in an off-licence manner that GPs were not aware of, as a 'stop-gap'
312	which was not best practice:

"What do you do when someone is presenting as severely anxious, mood difficulties,
not sleeping, incredibly chaotic: wait 18 months for therapy?... Do you simply adhere
to NICE recommendations and say... 'there's nothing I can do for you, you're going to
have to wait 18 months, it doesn't matter how distressed you are - just deal with it?"
(PSY-08)

It was felt that there needed to be more assistant psychologist posts to help manage 318 psychological demand, due to the fact it takes 5-6 years to fully train a clinical psychologist 319 320 and so few were available: "Some of these newer roles - the Clinical Associate in Applied Psychology, the 'CAAPS' 321 322 roles.... I don't want to call them the equivalent of physician associates, but they can work with people in the psychological model under supervision. They can do the 323 psychology, the formulations, they can deliver the interventions with support and 324 with supervision." (MDP-01) 325 326 327 (b) Pressure to discharge patients to primary care 328 Psychiatrists reported pressure from service managers to discharge patients, even those with SMI if they were stable from a psychiatric perspective, and especially those who did 329 330 not have a recognised psychotic illness. As a result of this transfer of patients to primary care, many GPs felt patients discharged would be unlikely to ever stop taking APM: 331 "There was a lot of pressure a few years ago on caseload cleansing, and there was 332 [a] bizarre diagram handed out: a huge pressure to [put] your caseload into one of 333 334 these four boxes.... the only ones we should be keeping were the 'complex and

- 335 unstable'.... and this is ridiculous... if I discharged [these patients] to primary care,
- 336 they'd be back in within two weeks." (PSY-01)

Many potential facilitators to reduce pressure to discharge patients to primary care were
raised by respondents. Managers felt the removal of numerical targets imposed by

339 governments as a measure of efficiency was needed – the preference being to measure

340	quality of outcomes rather than numbers of patients seen - to reduce pressure on mental
341	health teams to discharge patients. There was a recognition that many patients with chronic
342	SMI should remain under psychiatric care, with varying degrees of input, but as a minimum,
343	to have an annual review with a psychiatric specialist. GPs felt that proper shared-care
344	prescribing agreements should be in place for all antipsychotic prescribing, and discharge to
345	GPs only undertaken with mutual agreement by both services (MDP06):
346	"It not really shared-care a lot of the time. So once a 'shared-care' is in place,
347	secondary care often seems to think, they can then just discharge patients without
348	any agreement the problem is that don't tend to attach any funding to it. So, you
349	don't end up having the ability to be able to employ a mental health nurse to do the
350	antipsychotic reviewsI think the main difficulty is getting proper shared-care in
351	place, with the funding was attached, and you've then got the resources to do it
352	properly." (MDP05)

353

#### 354 (c) Difficulty to get psychiatric review for patients with cardiometabolic symptoms

GPs reported difficulty obtaining psychiatric review when cardiometabolic risks developed in those patients who were discharged to their care on APM. Psychiatrists often advised 'no change to APM' due to pressure on their appointments, so the chance to address cardiometabolic risk (e.g., by a change of APM to one with lower propensity for side effects such as weight gain) was missed due to resource limitations, rather than a decision based on clinical need:

361	"There's time pressure -if I've got someone stable and want to switch their
362	antipsychotic, then I'll have to give them more clinic appointments." (PSY-02)
363	In addition to the suggestion for formal shared-care agreements for all APM use, other
364	respondents suggested a formal mechanism for a 5-yearly specialist review of all patients
365	taking APM long-term in primary care. There was some debate, however, as to which
366	profession would be best placed to do these reviews, with suggestions including training
367	GPs with a specialist interest in mental health, community psychiatric nurse prescribers, or
368	pharmacists. Psychiatrists however, felt that it was unlikely these other professionals would
369	have the confidence to undertake reviews to reduce or withdraw APM, so should ideally be
370	undertaken by their own specialism:
371	"For that to happen, it would need to be done by the person with the most well-
372	developed sense of judgment of risk I think that would be a strong case to argue
373	for it being a psychiatrist doing it You could get somebody else doing it, but if they
374	were less confident taking somebody off medication is always a bit of a scary thing to
375	do. And it is always kind of tempting not to, because then you know what risks are
376	there in doing that? So, I would suggest it might be best for a psychiatrist to do it."
377	(PSY-03)
378	

#### 3/8

#### **379 3.** Communication barriers between primary and secondary care

Respondents felt that inadequate communication, both written, verbal, and in terms of
Information Technology (IT) access and integrated care, emerged as three subthemes which
inhibited better integrated care of patients prescribed APMs. GPs relayed how they rarely

had clear written discharge plans around ongoing APM use and struggled to get to speak to 383 psychiatrists directly for advice. Psychiatrists related how referrals they received often 384 lacked sufficient information to help manage patients, often from GPs who did not know the 385 patient. All respondents, including MDPs, highlighted the fragmented plurality of different IT 386 systems in primary and secondary care holding electronic health records (EHRs) in service 387 silos, making it difficult for teams to access all records to get a comprehensive overview of 388 389 the patient journey: 390 391 (a) Inadequate information in written handover

392 HCPs mentioned inadequate information in psychiatrist's letters on APM indication, 393 duration, and monitoring; GPs were often unaware when APM was prescribed 'off-licence' 394 and felt any anticipatory advice given was mostly only when to increase an APM to avoid the need to refer back to a psychiatrist. This left GPs with little confidence to make changes to 395 APM prescribing independently: 396 "As someone who completes discharge summaries, I'm going to hold my hand up and 397 398 say, we don't always include that... GPs get patients discharged on an antipsychotic 399 when they're 23 and they're still on the same antipsychotic at 43" (PSY-01) 400 Psychiatrists reported referral letters from GPs lacked detail and lack of personal knowledge 401 of the patient in the letter inhibited care, often only being a brief computer-collated GP 402 summary:

403	"Referral quality can be variable depending on the experience of the GP, and their
404	interest in mental health sometimes we [have to] go back and ask for more
405	information." (PSY-05)

406	Virtually all respondents felt that having standardised discharge and outpatient review
407	templates that indicated not only the current treatment but clear information on indication,
408	whether the APM was being used off-licence, intended duration, and suggested plan for
409	switching, weaning and reduction when safe to do so, would help support GPs to make APM
410	prescribing decisions, and that this should be performance managed as part of a shared care
411	agreement; many felt the only focus was on initiation and dose titration, and this was
412	insufficient to enable appropriate holistic care:

- 413 *"It would be useful if the [mental health team] said they're on this drug, which*
- 414 requires X, Y and Z monitoring, and we would expect them to stay on the drug for x
- 415 length of time. And I think they should say what the indication is and that it's being

416 *used off-licence."* (GP10)

417

(b) Difficulties in verbal communication between primary and secondary care.

GPs reported difficulties speaking to psychiatrists, with responses often from non-medical professionals unable to address their APM concerns, and psychiatrists felt GPs did not often know patients well enough to provide any useful context when they called to find out more about the patient:

423	"You often find - no disrespect to those health care workersqueries that we raise
424	are dealt with by health care workers way below the level of training of a consultant
425	psychiatrist." (GP-11)

426 "Because of the nature of general practice, you [often cannot] talk to a GP that
427 knows the patient personally... information that comes with the familiarity with the
428 patient that can be difficult to access." (PSY-07)

Some colleagues felt that services such as 'Consultant Connect' [27] were helpful, where a 429 430 GP could speak to a senior psychiatrist for advice, but because that consultant could be located anywhere in the UK and did not know the patient or have access to the patient 431 432 medical record, this was often quite limited when needing to discuss medication optimisation. Others felt that a local 'consultant of the day' who could take calls from GPs 433 would be more likely to improve decision making, as they would have EHR access to guide 434 435 management more effectively and document the advice given in the EHR. Psychiatrists also felt direct telephone numbers to GPs would improve communication. An indirect, but 436 437 related benefit of joint CPD training was also mentioned, in that teams would get to know 438 each other personally, which would improve mutual trust, problem-solving, and communication: 439

*"In [English Region], we developed a 'psychiatrist of the day' who would simply take calls from GP's, and it was amazing: the upskilling that results from that. The value of a local connection is twofold: One is, as a GP, I can seek advice about altering some of these medications, or whether or not they need referral right now.? Is there something else I can be doing with them? But two, also the 'psychiatrist of the day' gets to pick up what are the issues going on out there?' What's the common themes*

# 446 that perhaps we could do something about? Do we need an education event, or a

- 447 change to a pathway?" (MDP-09)
- 448

#### 449 (c) Poor integration of IT systems used in health services

Respondents highlighted that suboptimal IT systems inhibit HCP ability to manage patients
holistically, partly due to separate EHR systems commissioned by and used in primary and
secondary care services. HCPs often reported inability to view EHRs, resulting in wasted time
seeking information:

454 *"The hospital will have one electronic system, and the GP will have a second* 

455 electronic system. And then psychiatry has a third, even more separate, difficult to

456 access system, which some people have viewable access to, but not editable access."

457 (GP-07)

All respondents felt that improved access to shared records, utilising a common EHR system
across primary and secondary care, would improve integrated care. Many would like the
ability to add medications and have access to write into a common EHR, to avoid duplication
of effort, and ensure that all professionals were fully up to date with patient care.
Respondents recognised that patient confidentiality needed to be protected, but some felt
that an overemphasis on patient confidentiality, and having multiple EHR systems across the
health service, led to fragmentation of clinical records that impaired patient care, leading to

465 potential harm:

466 *"It is in every scenario - that kind of holy grail of the shared care record, it would sort*467 *it all out, it would solve it all."* (GP08)

23 of 39

#### 468

#### 469 4. HCPs have low expectations of patients taking APM

470	It became apparent that some HCPs had low expectations of patients with SMI. They found
471	them difficult to engage with therapeutically and described patients often missing
472	appointments, causing frustration for staff trying to help them. HCPs felt this was often due
473	to lack of motivation in the patient group. Other HCPs, however, felt that these patients
474	were disadvantaged by the health system, often faced discrimination, and were given
475	insufficient information on APM use to enable informed consent. This drove some HCPs to
476	act as advocates for their patients:
477	"They are not people who ask for helpthey're beaten down by the system as well,
478	and they accept their lot is just s***, and 'that's just the norm for me' "They are
479	seen to be a lost cause 'Oh, they will never give up smoking, so there's no point in
480	me asking' And not only that, but it's also their own fault - it's the opposite of the
481	truth, isn't it reallyThey respond well to having someone who is interested in them
482	I'm not sure I make a massive difference we're there to pick stuff up when things go
483	wrong, and start metformin when they inevitably become diabetic, or write the death
484	certificate when they die young. You know, it feels a bit depressing to just verbalize
485	<i>it." (</i> GP-08)

Many HCPs felt that tackling lowered expectations towards patients with SMI was
challenging, and this mirrored societal attitudes. However, one MDP who represented
patients from a mental health charity, did report that they felt GPs who had undertaken
psychiatric training were more likely to be able to challenge and act as advocates for

patients, and that postgraduate psychiatric training should be mandated in the GP trainingprogramme:

492	"I think with GP training, you maybe get one opportunity to spend time on a mental
493	health ward, and I know from speaking to GPs, that those GP's that have done that
494	understand the system better in terms of referrals they are better able to challenge
495	it and to be an advocate on behalf of their patients." (MDP02)

496

#### 497 **5. Strategic factors affecting APM prescribing in primary care**

Participants identified multiple professional and organisational constraints acting as barriers 498 to optimise APMs. Three main subthemes emerged; the first subtheme focussed on the 499 500 difficulties with the contractual split between primary and secondary care, with the UK GP General Medical Services (GMS) contract and narrow criteria for patient inclusion on the 501 502 Quality and Outcomes Framework (QOF) mental health register, meant many patients now prescribed APM in primary care for non-psychotic illness were not being monitored 503 effectively. Organisational competition and 'protectionism' for resources were mentioned, 504 505 meaning patients could be disadvantaged by siloed care largely dictated by organisational 506 budgetary constraints. A second theme centred around socioeconomic deprivation and medicalisation of distress driving APM use. A final theme described the fear many HCPs had 507 508 around stopping or changing APMs in case an adverse event occurred that would render 509 them liable to 'societal blame' or censure by regulatory bodies:

510

511

#### 512 (a) Contractual divisions between primary and secondary care

513	Psychiatrists and MDPs felt the UK General Medical Services (GMS) GP contract structure
514	inhibited shared care:

- Sometimes it's the GMS contractual issues... that constant argument around "I'm
  not going to do this unless [GPs] get paid for it". Those sorts of issues really need to
  be addressed... sometimes we forget there's a patient at the end of all these
- 518 *decisions."* (MDP-08)
- 519 The Quality and Outcomes Framework (QOF) in the UK GMS contract incentivises GPs to
- 520 monitor physical health risks for patients with SMI, but incentives have been largely
- abolished in GMS contract revisions in Wales and Scotland; GPs felt this would deter
- 522 ongoing monitoring. Many were concerned the QOF 'mental health register' criteria, being
- 523 focussed almost exclusively on psychotic illness such as schizophrenia or bipolar affective
- 524 disorder, did not capture all patients prescribed APM, so there was a risk many patients
- 525 were not reviewed comprehensively:
- 526 "In England, we still have the [QOF] mental health register.... but it doesn't pick up
  527 people who've got a personality disorder." (GP-04)
- Respondents reported tensions between organisations contributed to protectionism that
  impaired care. A former Royal College officer reported conflicts of interest between
  representing members' interests, and serving patients:
- 531 *"There is a real tension between being a member's organization that needs to deliver*
- 532 for its members' interests, and doing the right thing..., I was there representing
- 533 [Royal College] ... we can see what the right thing is to do, but as membership

534	organizations, we have to protect the needs of our members. So, you would not
535	expect the Royal College of GPs to meet with the Royal College of Psychiatrists and
536	[say] "You have all the money we get for mental health, and you just sort out
537	everything"protectionism gets in the way of better care." (MDP-04)
538	Some respondents felt influence of patient groups and political targets could skew resource
539	allocation:
540	"When you're taking a massive stack of antipsychotics, with all the negative impact
541	that has on motivation those patients are the ones that I feel are most neglected
542	by mental health services the patient groups that talk the loudest, are [those] who
543	we perhaps have the least value to offerthe patient groups who have the smallest
544	voice need the most attention." (PSY-07)
545	MDPs felt frustrated attempts to address APM overprescribing did not result in savings to
546	reinvest in services such as psychology:
547	"Prescribing budgets are held in a different part of the [NHS organisation] I can't
548	get hold of prescribing budgets, even if I've saved on one element of them to reinvest
549	the savings." (MDP-06)
550	Many respondents felt that contractual divisions between primary and secondary care
551	created barriers, for example around ability to refer to weight management clinics being
552	restricted to primary care, and service commissioners and providers needed to facilitate
553	pathways that allowed ease of referral for interventions from all HCPs. Others felt that there
554	was a need for more joint working between Royal Colleges, the British Medical Association
555	and service providers to identify gaps in holistic provision and the need to alter the funding

556	mechanisms to overcome these. Many HCPs highlighted that APM prescribing should
557	indicate ongoing monitoring, rather than specific SMI diagnoses, as currently occurred in the
558	QOF mental health register:
559	"I think the Royal colleges and others come together really well on single pieces of
560	work, but actually our chances of getting the Academy of Royal Colleges to say,
561	"Primary care is the way forward. Disinvest from all your fancy hospital services and
562	spend the money where they make the biggest difference", there is zero chance, even
563	though every leader in the Academy of Royal Colleges can intellectually appreciate
564	the benefit." (MDP04)
565	
566	(b) Worsening inequality driving antipsychotic use
566 567	(b) Worsening inequality driving antipsychotic use Respondents often felt antipsychotic use was a 'stop-gap' to deal with consequences of
566 567 568	(b) Worsening inequality driving antipsychotic use Respondents often felt antipsychotic use was a 'stop-gap' to deal with consequences of socioeconomic inequality and the medicalisation of distress, which health services could not
566 567 568 569	(b) Worsening inequality driving antipsychotic use Respondents often felt antipsychotic use was a 'stop-gap' to deal with consequences of socioeconomic inequality and the medicalisation of distress, which health services could not address directly, and the patient primarily needed social interventions regarding finances,
566 567 568 569 570	<ul> <li>(b) Worsening inequality driving antipsychotic use</li> <li>Respondents often felt antipsychotic use was a 'stop-gap' to deal with consequences of</li> <li>socioeconomic inequality and the medicalisation of distress, which health services could not</li> <li>address directly, and the patient primarily needed social interventions regarding finances,</li> <li>housing, or education:</li> </ul>
566 567 568 569 570 571	(b) Worsening inequality driving antipsychotic use Respondents often felt antipsychotic use was a 'stop-gap' to deal with consequences of socioeconomic inequality and the medicalisation of distress, which health services could not address directly, and the patient primarily needed social interventions regarding finances, housing, or education: <i>"We go at stuff from the health level viewUntil we're able to deal with the fact</i>
566 567 568 569 570 571 572	(b) Worsening inequality driving antipsychotic use Respondents often felt antipsychotic use was a 'stop-gap' to deal with consequences of socioeconomic inequality and the medicalisation of distress, which health services could not address directly, and the patient primarily needed social interventions regarding finances, housing, or education: "We go at stuff from the health level viewUntil we're able to deal with the fact [people] can't feed their kids, or heat their homes, that schools don't have the
566 567 568 569 570 571 572 573	(b) Worsening inequality driving antipsychotic use Respondents often felt antipsychotic use was a 'stop-gap' to deal with consequences of socioeconomic inequality and the medicalisation of distress, which health services could not address directly, and the patient primarily needed social interventions regarding finances, housing, or education: <i>"We go at stuff from the health level viewUntil we're able to deal with the fact [people] can't feed their kids, or heat their homes, that schools don't have the resources to put into troubled young people. [antipsychotic prescribing] is not going</i>
<ul> <li>566</li> <li>567</li> <li>568</li> <li>569</li> <li>570</li> <li>571</li> <li>572</li> <li>573</li> <li>574</li> </ul>	(b) Worsening inequality driving antipsychotic use Respondents often felt antipsychotic use was a 'stop-gap' to deal with consequences of socioeconomic inequality and the medicalisation of distress, which health services could not address directly, and the patient primarily needed social interventions regarding finances, housing, or education: "We go at stuff from the health level view Until we're able to deal with the fact [people] can't feed their kids, or heat their homes, that schools don't have the resources to put into troubled young people. [antipsychotic prescribing] is not going to reduce in our medicalized society I can absolutely see why [antipsychotic
566 567 568 569 570 571 572 573 574 575	(b) Worsening inequality driving antipsychotic use Respondents often felt antipsychotic use was a 'stop-gap' to deal with consequences of socioeconomic inequality and the medicalisation of distress, which health services could not address directly, and the patient primarily needed social interventions regarding finances, housing, or education: <i>"We go at stuff from the health level viewUntil we're able to deal with the fact [people] can't feed their kids, or heat their homes, that schools don't have the resources to put into troubled young people. [antipsychotic prescribing] is not going to reduce in our medicalized society I can absolutely see why [antipsychotic prescribing] rates are rising." (MDP-04)</i>
566 567 568 569 570 571 572 573 574 575 576	(b) Worsening inequality driving antipsychotic use Respondents often felt antipsychotic use was a 'stop-gap' to deal with consequences of socioeconomic inequality and the medicalisation of distress, which health services could not address directly, and the patient primarily needed social interventions regarding finances, housing, or education: <i>"We go at stuff from the health level viewUntil we're able to deal with the fact [people] can't feed their kids, or heat their homes, that schools don't have the resources to put into troubled young people. [antipsychotic prescribing] is not going to reduce in our medicalized society I can absolutely see why [antipsychotic prescribing] rates are rising." (MDP-04)</i> Another common area of concern was around pressure from relatives and care home staff

578	this was largely down to inadequate training, retention and recruitment of carer staff who
579	have the skills to manage patients with behavioural difficulties using non-pharmacological
580	methods. Many respondents felt powerless to address the wider socioeconomic
581	determinants driving increasing mental distress in the community but recognised that this
582	had to be addressed as a political priority that encompassed services beyond health. A
583	number however felt that investment in better training and retention of skilled care home
584	staff would reduce APM prescribing in elderly patients:
585	"So, for example, care homes are running on empty. They don't have people who are
586	skilled they have token specialist dementia champions, but they just don't have the
587	resources to sit with people while their anxiety levels reduce, or engage them with
588	memory rooms, and things that we know improve or reduce the need for
589	antipsychotic use." (GP-04)
590	

### 591 (c) Medicolegal and regulatory fears of HCPs

592 HCPs mentioned fears around stopping APMs if a patient subsequently harmed themselves 593 or others; some felt they 'prescribe to be seen to do something' due to working in an 594 unforgiving regulatory culture:

"If I was to stop an antipsychotic...if something adverse happened, I think I would
have a very difficult time justifying that action, even if it's a relatively safe thing to
[do]... those things lead to medication overprescribing... even if it's the wrong thing

to do, it's almost a sense that having done something is better than doing nothing."
(GP-04)

600	Psychiatrists reported unrealistic societal expectations that an adverse outcome must
601	'always be someone's fault' which inhibited their willingness to deprescribe:
602	"Physicians accept that there's a certain percentage of COPD patients who will die,
603	that it doesn't matter much resource you usethey will get worse, and some of those
604	people will die. And then there is a very marked reluctance [within society] to
605	accept that [psychiatric] conditions also have a morbidity and mortality which I find
606	frustrating." (PSY-07)

Many respondents felt that, at times, a degree of over-regulation created barriers, in that it inhibited ability to devise appropriate care pathways and encouraged defensive clinical practice. They mentioned that the regulators did not seem to recognise that this stifled ability to innovate at times and did not seem to recognise that overzealous regulation could paradoxically lead to indirect patient harm, and so wanted a debate around the culture in which they had to practice.

613 One final unintended consequence of overzealous performance management that appeared 614 to contribute to increased APM use was around prescribing indicators for benzodiazepines being closely monitored by national medicines management teams, with targets being to 615 616 achieve a reduction in their use. As a result, this was often given as feedback to clinicians in quarterly reports on their prescribing activity, and many felt unfairly scrutinised as a result. 617 Some practitioners thus 'gamed they system' by switching to using sedating APMs (e.g., 618 619 quetiapine) to treat insomnia rather than using benzodiazepines, as this was not monitored 620 at the national level, and thus some MDPs suggested that the wider use of off-licence APM needed to be monitored also: 621

"I'm quessing if we use diazepam as an example - diazepam was the elixir for 622 everything. And we had, going back, a massive uptake in the prescription of 623 diazepam. We are aware of the issue of diazepam now has, in a sense of its 624 addiction... so we just turn to other medication with a similar effect; in this case it is 625 antipsychotics." (PSY-04) 626 627 DISCUSSION 628 629 Summary Our research shows how HCPs and MDPs reported competency gaps that impaired HCP 630 ability to manage the varied mental and physical health needs of patients' prescribed APMs 631 632 appropriately. Stakeholders suggested that deficiencies in postgraduate experience and professional development contributed to GPs and psychiatrists' lack of confidence to 633 634 manage both the mental health and physical health aspects of APM management. Lack of postgraduate GP experience for psychiatrists inhibited their understanding of GP 635 competences. Communication barriers, lack of integrated care records, limited resources, 636 637 particularly in relation to psychology provision, and perceived pressures to move patient 638 care back to GPs ultimately resulted in patients in primary care being 'trapped' on APM, inhibiting opportunities to deprescribe, and increasing cardiometabolic risk in the longer 639 term. Organisational and contractual barriers between services exacerbated risks, with 640 socioeconomic deprivation driving overprescribing. Both GPs and psychiatrists voiced 641 professional fears of being blamed if an event causing harm occurred after stopping an 642 643 APM, which inhibited deprescribing confidence. Many respondents had low expectations of patients with SMI, which also contributed to care deficiencies. These factors act at several 644 31 of 39

649	[insert Figure 1]
648	Figure 1: Pathway of patient care on antipsychotics and barriers to better integrated care
647	
646	accretion of cardiometabolic risk in this patient group in primary care (Figure 1).
645	points in the care pathway and contribute to the increasing prevalence of APM use and

650

#### 651 Strengths and Limitations

This study examines reasons for increasing APM prevalence in primary care. We had input 652 653 from team members from different professions (medicine, pharmacy, health research), medical specialities (general practice, psychiatry, clinical pharmacology, public health) and 654 the study sought views of those managing services, helping shape mental health policy and 655 656 contractual arrangements, and involved in postgraduate training. We recruited participants 657 from across three UK nations, to minimise bias that might result from one health region. Data saturation was achieved. However, participation, which was voluntary, may mean 658 participants had a particular interest in the problem, and we may not have acquired views of 659 660 less interested clinicians, so there is a risk of recruitment bias. Finally, this is a qualitative study that identifies perceived issues of concern in relation to APM management, but it 661 662 does not provide information about the relative importance of the different themes identified. Also, the work is undertaken in the UK, and while there may be similarities with 663 other high-income countries there will also be differences worthy of exploration to better 664 665 understand common international issues. Finally, this study does not seek the views of

666 patients who are prescribed APM and managed solely in primary care; a separate qualitative 667 study examining this is currently underway.

668

#### 669 Comparison with existing literature

670 This is the first study to examine management of APM for patients discharged to primary 671 care, which makes comparisons difficult, but other studies partially consider this. Nash et al [20] examined decision-making around APM switching by psychiatrists and GPs in one 672 673 health region in England but did not specifically consider patients managed solely in primary care. This work and other studies conducted with patients and professionals in the 674 675 Netherlands reported similar themes: concerns around jeopardising mental health by 676 switching APMs to reduce cardiometabolic risk was mentioned as a reason not to do so, 677 poor engagement with patients to make informed decisions, and diffusion of responsibility with respect to managing cardiometabolic risks secondary to APM use [5, 20]. Several 678 studies in the UK, Netherlands and Canada confirm difficulties in communication and 679 680 collaboration between primary and secondary care inhibits integrated care for people 681 taking APM [20, 28-31]. Moncrieff et al examined patient and HCP factors acting as barriers 682 to deprescribing of APM in the UK [32] and reported concerns about relapse and potential harms to the patient, but this did not elucidate concerns of the HCPs around medicolegal or 683 regulatory risks to their professional role. Our data confirms these findings, and extend 684 685 them, showing that factors including HCP training, contractual, organisational, and 686 medicolegal factors also act as barriers to better person-centred care in the UK.

687

688	Implications for future research and clinical practice
689	Our findings suggest several practical actions policymakers and practitioners can take now
690	to improve person-centred care for people on APM, which we summarise in Figure 2:
691	
692	Figure 2: Potential actions to improve integrated care for patients taking antipsychotics
693	discharged to primary care
694	[insert figure 2]
695	
696	This will require action at several organisational levels, including changes to postgraduate
697	curriculum design for both general practice and psychiatry, evidence-based guidance on
698	APM prescribing duration in non-psychotic illness, greater investment in non-
699	pharmacological resources and input from professional regulators to address HCP fears
700	around a 'blame culture' that exists currently. Our analysis suggests that addressing
701	competency gaps and communication barriers between primary and secondary care are
702	those which are likely most amenable to change locally within health service organisations.
703	Implementing structured discharge letters and mandatory use of shared care protocols are
704	relatively easy to implement to improve integrated care of patients taking APM. Psychiatric
705	inpatients usually have considerable physical health data collated during admission that
706	allows accurate quantification of cardiovascular disease risk, but these are not always acted
707	on by psychiatric teams; training to ensure appropriate pharmacological interventions are
708	undertaken is needed [33]. Modification of care pathways for non-pharmacological
709	interventions to allow referral by mental health staff, regular reviews by competent HCPs

710 able to optimise or withdraw APM, and appointment of staff to provide support to patients 711 that is non-pharmacological may be harder to achieve. Particular challenges exist in terms of 712 capacity in terms of psychological provision, but also within in the social care sector with 713 staff capable of managing behavioural consequences of dementia without recourse to APM 714 use. The wider societal factors, around attitudes towards patients with SMI and dealing with 715 socioeconomic factors increasing mental distress are beyond local action and require a co-716 ordinated national approach. It is also clear that well-intentioned performance management 717 and regulation may paradoxically contribute to increasing prevalence of patients on APM in 718 primary care. HCPs increasingly use APM as an alternative to benzodiazepine use for 719 insomnia and anxiety, due to the latter being closely monitored as a quality prescribing 720 indicator in some regions; medicines management teams should consider the wider use of 721 APM for non-psychotic illness in their performance indicators. The wider regulatory milieu in 722 which HCPs perceive they are working is leading to defensive practice, where patients are 723 left on APM due to fear of professional censure should a catastrophic adverse event occur if 724 HCPs reduce or withdraw the medication. Regulators need to reassure HCPs that this is 725 unlikely to occur, as this was a common concern for HCPs; a national debate on this is required. 726

Further research is required to explore experiences of patients prescribed APMs discharged to primary care, and to examine if similar barriers to person-centred, integrated care exist internationally in other health systems where primary and secondary care operate in an analogous manner to the UK (e.g., Australia, New Zealand, Ireland, Canada). Studies have examined attitudes of patients taking antipsychotics regarding their management and physical health [30], but none formally examined the growing proportion of patients

733	prescribed APM no longer under psychiatric review. Further study is needed of clinical and
734	postgraduate educational policies in the UK and elsewhere that have contributed to
735	fragmented services with HCPs, particularly in secondary care having inadequate
736	understanding of the primary care context. The theme of regulatory fear is also evident in
737	HCPs treating patients with SMI and acts as a barrier to deprescribing of APM. This needs
738	further exploration internationally, with regulators, patients, and HCPs together – to
739	consider how the regulatory and performance management 'observer effect' may impair or
740	distort clinical practice.

741

#### 742 CONCLUSIONS

There is considerable risk that the increasing use of APM in society is inadequately 743 managed. Unless we address the factors that contribute to fragmented and suboptimal care 744 745 for those taking APM, poor long-term outcomes in terms of increased rates of cardiometabolic disease will be difficult to ameliorate. The theme of regulatory fear by HCPs 746 747 is a new factor emerging as a barrier to deprescribing of APM, and this needs further examination in other studies to determine if this is an international concern. Many changes 748 could easily be made to improve person-centred, integrated care of those on APM with 749 750 minimal need for change by health service organisations. However, other issues such as 751 inadequate availability of non-pharmacological alternatives to APM and socioeconomic factors increasing mental distress will require national leadership by key stakeholders to 752 753 improve the current situation.

754

- Acknowledgements: We thank the generous input of the participants who took part in theinterviews.
- 757 Contributors: AW, FM, SS, IB and LW conceived the study and wrote the application for
- funding and the protocol. PS provided public perspective on the study design and results.
- AW conducted the data collection. AW, AA, SW and LW undertook the primary coding and
- thematic analysis, and all other authors (PA, FM, SS, DJ, IB) contributed to the data analysis
- and discussion. AW and LW drafted the manuscript, and all authors commented on the
- 762 manuscript.
- 763 Funding: This work was funded by a Research Time Award to AW from Health and Care
- 764 Research Wales (NHS-RTA-21-02).
- 765 **Competing interests:** None declared.
- 766 **Consent for Publication:** Not Required.
- 767 **Ethical Approval and Governance:** The study received ethical approval from the Health
- 768 Research Authority (IRAS: 311503) via NHS Research Ethics Committee-06 (22/WA/0173).
- 769 **Provenance and Peer Review:** Not commissioned; externally peer reviewed.
- 770 Data availability statement: Data are available from the corresponding author on
- 771 reasonable request.
- **Supplemental material**: Study protocol, semi structured interviews template, additionalquotes.
- 774 **Open access:** Put in relevant licence.
- 775

medRxiv preprint doi: https://doi.org/10.1101/2023.11.13.23298487; this version posted November 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

## perpetuity. It is made available under a CC-BY 4.0 International license .

#### 776 REFERENCES

- 777 1. Hayes JF. Marston L, Walters K, King MB, Osborn DPJ. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014. Br J Psychiatry, 2017. 211(3): 778 779 175-181. Pubmed PMID: 28684403
- 780 2. John A, McGregor J, Jones I, Lee SC, Walters JTR, Owen MJ et al. Premature mortality among 781 people with severe mental illness - New evidence from linked primary care data. Schizophr 782 Res, 2018. 199: 154-162. Pubmed PMID: 29728293
- 783 3. Walker, ER., McGee RE, Druss BG. Mortality in Mental Disorders and Global Disease Burden 784 Implications: A Systematic Review and Meta-analysis. JAMA Psychiatry, 2015. 72(4): 334-785 341. Pubmed PMID: 25671328
- 4. 786 Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among 787 patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, 788 789 and schizophrenia. J Clin Psychiatry, 2007. 68(6): 899-907. Pubmed PMID: 17592915
- 790 5. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse 791 effects associated with antipsychotic drugs. Nat Rev Endocrinol, 2011. 8(2): 114-26. Pubmed 792 PMID: 22009159
- 793 6. Roberts R, Neasham A, Lambrinudi C, Khan A. A quantitative analysis of antipsychotic 794 prescribing trends for the treatment of schizophrenia in England and Wales. JRSM Open, 795 2018. 9(4): 2054270418758570. Pubmed PMID: 29707225
- 796 7. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or 797 cardiometabolic risk? Acta Psychiatr Scand, 2009. 119(3): 171-179. Pubmed PMID: 798 19178394
- 799 8. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and 800 clinical implications. CNS Drugs, 2007. 21(11): 911-36. Pubmed PMID: 17927296
- 801 9. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and 802 sudden death. Drugs, 2002. 62(11): 1649-71. Pubmed PMID: 12109926
- 803 10. Mwebe H, Volante M, Weaver T. Monitoring cardiovascular disease risk in individuals with 804 severe mental illness in an inpatient mental health setting: a secondary data analysis. Br J 805 Card Nurs, 2020. 9(3): 1-14. doi.org/10.12968/bjca.2020.0157
- 806 11. Hardoon S, Hayes J, Viding E, McCrory E, Walters K, Osborn D. Prescribing of antipsychotics 807 among people with recorded personality disorder in primary care: a retrospective 808 nationwide cohort study using The Health Improvement Network primary care database. 809 BMJ Open, 2022. 12(3): e053943. Pubmed PMID: 35264346
- 810 Gerhard T, Stroup TS, Correll CU, Huang C, Tan Z, Crystal S et al. Antipsychotic Medication 12. 811 Treatment Patterns in Adult Depression. J Clin Psychiatry, 2018. 79(2). Pubmed PMID: 812 28686818
- 813 13. Comer JS, Mojtabai R, Olfson M. National Trends in the Antipsychotic Treatment of 814 Psychiatric Outpatients With Anxiety Disorders. Am J Psychiatry, 2011. 168(10): 1057-1065. 815 Pubmed PMID: 21799067
- 816 Khaledi-Paveh B, Maazinezhad S, Rezaie L, Khazaie H. Treatment of chronic insomnia with 14. 817 atypical antipsychotics: results from a follow-up study. Sleep Sci, 2021. 14(1): 27-32. 818 Pubmed PMID: 34104334
- 819 15. Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a 820 systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis, 2016. 821 7(5): 229-45. Pubmed PMID: 27583123
- Alexander RT, Shankar R, Cooper SA, Bhaumik S, Hastings R, Kapugama CL et al., Challenges 822 16. 823 and pitfalls of antipsychotic prescribing in people with learning disability. Br J Gen Pract, 824 2017. 67(661): 372-373. Pubmed PMID: 28751349

825 17. Posey DJ, Stigler KA, Erikson CA, McDouble CJ. Antipsychotics in the treatment of autism. J 826 Clin Invest, 2008. 118(1): 6-14. Pubmed PMID: 18172517 827 Psychoses and related disorders. In: Joint Formulary Committee, British National Formulary 18. 828 [internet]. London: British Medical Association and Royal Pharmaceutical Society of Great 829 Britain; [cited 2023 Oct 23]. Available from: https://bnf.nice.org.uk/treatment-830 summaries/psychoses-and-related-disorders/ 831 19. Kjosavik SR, Hunskaar S, Aarsland D, Ruths S. Initial prescription of antipsychotics and 832 antidepressants in general practice and specialist care in Norway. Acta Psychiatr Scand, 833 2011. 123(6): 459-465. Pubmed PMID: 21401533 834 20. Nash A, Kingstone T, Farooq S, Tunmore J, Chew-Graham CA. Switching antipsychotics to 835 support the physical health of people with severe mental illness: a qualitative study of healthcare professionals' perspectives. BMJ Open, 2021. 11(2): e042497. Pubmed PMID: 836 837 33637542 838 Woodall A. Managing patients on atypical antipsychotics in primary care. Prescriber, 2021. 21. 839 32(11-12): 18-23. doi.org/10.1002/psb.1952 840 22. Nicaise P, Giacoo D, Soltmann B, Pfennig A, Miglietta E, Lasalvia A et al. Healthcare system 841 performance in continuity of care for patients with severe mental illness: A comparison of 842 five European countries. Health Policy, 2020. 124(1): 25-36. Pubmed PMID: 31831211 843 23. Marston L, Nazareth I, Petersen I, Walters K, Osborn DP. Prescribing of antipsychotics in UK 844 primary care: a cohort study. BMJ Open, 2014. 4(12): e006135. Pubmed PMID: 25524544 845 24. Reilly S, Planner C, Hann M, Reeves D, Nazareth I, Lester H. The role of primary care in 846 service provision for people with severe mental illness in the United Kingdom. PLoS One, 847 2012. 7(5): e36468. Pubmed PMID: 22615769 848 25. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research 849 (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care, 2007. 850 19(6): 349-357. Pubmed PMID: 17872937 851 Braun V, Clark V. Using thematic analysis in psychology. Qual Res Psychol, 2006. 3(2): 77-26. 852 101. doi.org/10.1191/1478088706qp063oa 853 Consultantconnect.org.uk [internet]. Oxford UK; c2023 [cited 2023 Oct 23]. Available from: 27. 854 https://www.consultantconnect.org.uk/. 855 28. Kozlowska O, Lumb A, Tan GD, Rea R. Barriers and facilitators to integrating primary and specialist healthcare in the United Kingdom: a narrative literature review. Future Healthc J, 856 857 2018. 5(1): 64-80. Pubmed PMID: 31098535 858 29. Ross LE, Vlgod S, Wishart J, Waese M, Spence JD, Oliver J et al., Barriers and facilitators to 859 primary care for people with mental health and/or substance use issues: a qualitative study. 860 BMC Fam Pract, 2015. 16: 135. Pubmed PMID: 26463083 861 30. van Hasselt FM, Oud MJ, Loonen AJ. Improvement of care for the physical health of patients 862 with severe mental illness: a qualitative study assessing the view of patients and families. 863 BMC Health Serv Res, 2013. 13: 426. Pubmed PMID: 24144438 864 31. van Hasselt FM, Oud MJ, Loonen AJ. Practical recommendations for improvement of the physical health care of patients with severe mental illness. Acta Psychiatr Scand, 2015. 865 866 131(5): 387-96. Pubmed PMID: 25495118 867 32. Moncrieff JS, Gupta S, M.A. Horowitz MA, Barriers to stopping neuroleptic (antipsychotic) 868 treatment in people with schizophrenia, psychosis or bipolar disorder. Ther Adv 869 Psychopharmacol, 2020. 10: 2045125320937910. Pubmed PMID: 32670542 870 33. Woodall A, Prosser A, Griffiths M, Shooter B, Garfitt J, Walker L, Buchan I. Cardiovascular risk 871 estimation in rural psychiatric inpatient populations: Cross-sectional preliminary study. Psychiatry Res Commun, 2023. 3(1): 100103. Pubmed PMID: 37654699 872 873

## Figure 1: Pathway of patient care on antipsychotics and barriers to better integrated care



Figure showing barriers to care

Theme	Sub-theme	Problem	Action	Suggested solution	Action to achieve by:
			possible now?		
Confidence of	GPs reluctant to manage	GPs Lack confidence	Yes	Structured letters* from psychiatrists give clear advice on	Directors of Mental
HCPs around	APM without psychiatrist	to trial APM		indication, duration, switching, and dose of APMs before	Health services
holistic	support	optimisation		discharge, and confirm discussion with patient.	
management	Psychiatrists reluctant to	Psychiatrists not	Yes	Support for psychiatrists: Employment of GPs in advisory	Directors of Mental
of APM	address cardiometabolic	addressing physical		roles to support cardiometabolic interventions while under	Health services
	risk	health risk		psychiatric care.	
				Support staff to co-ordinate physical health monitoring and interventions	
	Gaps for HCP in	Training does not	No	Co-ordination of postgraduate curriculum design by Royal	National priority
	postgraduate and post-	cover the full range		College of General Practitioners and Royal College of	setting by Royal
	speciality training	of skills to provide		Psychiatrists	Colleges
		holistic are		Mandatory primary care experience in postgraduate	
				training for all psychiatry trainees.	
Service	Limited psychology	Lack of psychology	No	Employ clinical associates in applied psychology to increase	Accountable officer of
pressures	provision	driving APM use		psychological therapy capacity.	health providers;
'trapping'				Savings in psychotropic medication use earmarked for	Directors of Mental
antipsychotics				investment in psychological provision.	Health services
in primary care	Pressure to discharge	Limited psychiatric	No	Formal shared care agreements for antipsychotics before a	National priority
	patients to primary care	appointment		patient can be discharged to primary care with mandated	setting
		resource		plan on future cessation and withdrawal.	
	Difficulty to get psychiatric	Limited psychiatric	No	Formal shared care agreements to include a 5 yearly	National priority
	review for patients with	appointment		mandated review by psychiatrist to determine if ongoing	setting
	cardiometabolic risks	resource		antipsychotic use is needed.	
				Train pharmacists to proactively address cardiometabolic	
				risk in pharmacy and GP settings	
Communication	Inadequate information in	Inadequate advice	Yes	Structured letters* (see above).	Directors of Mental
barriers	written handover	in discharge letters			Health services
between	Plffindelander et al.	to GPs	Death	Blanch to be the set of the set o	Discology of the second
primary and	Dimculties in verbal	Barriers to verbal	Partiy	Direct telephone lines to "duty medical professional"; use	Directors of II, Mental
secondary care	communication between	communication		or alternative communication (e.g., Microsoft Teams) to	Health services,
	primary and secondary care			make contact easier.	Primary Care

	Poor integration of IT systems used in health services	Inadequate access to care records	Partly	Ensure all clinicians have a minimum of 'read access' to summary care records (GP and mental health records) Adoption of a common electronic health record system across the primary and secondary care estate with shared read-write access.	Directors of IT
HCPs have low expectations o patients taking APM	Low expectations included feeling patients won't engage, are not motivated, and discriminatory risks	Attitudes of HCPs	Partly	Challenge attitudes and look at different ways to engage patients with SMI which reduce inequality of access to care	Directors of mental health services and primary care; National priority setting
Strategic factors affecting APM	Contractual divisions between primary and secondary care	QOF registers inadequate	Partly	Ensure each GP practice has register of patients on antipsychotics with performance management of monitoring and use by commissioners of services	Directors of primary care; National priority setting
prescribing in primary care	Worsening inequality driving antipsychotic use	Socioeconomic deprivation causing distress	No	Redistribution of resources to improve mental health resilience.	National priority setting
	Medicolegal and regulator fears by HCPs.	HCP fear of censure	Partly	Regulators to reassure healthcare professionals; set up a joint committee to investigate and report on unintended harms of the regulatory environment impacting on psychiatric patient care. Consider use of antipsychotics in non-SMI illness for prescribing performance indicators.	National priority setting; Medicines management teams